NCT01414309终止不适用
Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
Respicardia, Inc.4 个研究点 分布在 2 个国家目标入组 5 人开始时间: 2011年8月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- Apnea-hypopnea index and its components
研究概览
简要总结
Central sleep apnea (CSA) has been associated with increased mortality and primarily occurs in patients with heart failure (HF). The primary purpose of this study is to document the natural progression of moderate to severe CSA in heart failure patients.
详细描述
This trial is a prospective, non-randomized observational study in heart failure patients with moderate to severe central sleep apnea (CSA).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is willing and able to comply with this protocol and has signed an IRB/MEC approved informed consent (as well as Privacy Protection Authorization in the United States)
- •Age is greater than or equal to 18 years
- •Known recent history of sleep disordered breathing of predominantly central origin, as evidenced by an overnight PSG with EEG and at least 4 hours of recording that was conducted within 60 days of enrollment and demonstrating the following characteristics:
- •AHI greater than or equal to 20
- •greater than or equal to 50% of classified events of a central nature
- •less than 20% of the total AHI comprised of obstructive apnea events
- •Diagnosed chronic heart failure, with medications optimized and stable for at least 30 days prior to the screening PSG, or since the date of the earliest test used for baseline, whichever is longer. Optimal medications include: beta blockade, ACE-I or ARB and diuretics unless contraindicated or not considered medically necessary.
排除标准
- •Current or intended use of any mask-based therapy for central sleep apnea
- •Baseline oxygen saturation less than or equal to 90% on a stable FiO2
- •Severe Chronic Obstructive Pulmonary Disease (COPD) (per GOLD classification system)
- •History of cerebrovascular accident (CVA), myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery, or percutaneous coronary intervention (PCI), or any cardiac ablation procedure within the 3 months prior to the study
- •Unstable angina
- •History of primary pulmonary hypertension
- •Currently enrolled in a non-observational (ie, interventional) clinical study that could confound the results of this study
- •If subject has an implanted cardiac resynchronization device (CRT), it must have been implanted at least 3 months before enrollment; any other device must have been implanted at least 30 days prior to enrollment
- •Life expectancy of less than 6 months
结局指标
主要结局
Apnea-hypopnea index and its components
时间窗: 6 months
The primary objective of the study is to determine the natural progression of central sleep apnea, using the apnea-hypopnea index (AHI) and its components evaluated at 6 months.
次要结局
- Clinical status associated with sleep disordered breathing(6 months)
研究者
研究点 (4)
Loading locations...
相似试验
暂停
不适用
The Effect of CRT on the Hypercapnic Ventilatory ResponseSleep Disordered BreathingHeart FailureNCT02203383Royal Brompton & Harefield NHS Foundation Trust40
已完成
不适用
Central Sleep Apnea Prevalence and Impact on Cognitive Function in Patients with Heart Failure with Reduced or Mildly Reduced Left Ventricular Ejection FractionHeart FailureCentral Sleep ApneaNCT06313840Zoll Medical Corporation200
招募中
4 期
Central Sleep Apnea : Physiologic Mechanisms to Inform TreatmentSleep Disordered BreathingAble BodiedNCT04118387VA Office of Research and Development200
终止
不适用
Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart FailureSleep ApneaHeart FailureNCT01128816Toronto Rehabilitation Institute732
已完成
不适用
Sleep Apnea in Heart Failure With Preserved Ejection FractionObstructive Sleep ApneaHeart FailureNCT05008432Mayo Clinic48